Loading organizations...

§ Private Profile · Houston, TX, USA
biotechnology company develops immuno-corrective therapies for autoimmune patients, targeting sIL7R with precision medicine.
Autoimmunity BioSolutions has raised $2.0M across 1 funding round.
Autoimmunity BioSolutions has raised $2.0M in total across 1 funding round.
Autoimmunity BioSolutions is a biotechnology company based in an undisclosed location that develops next-generation immuno-corrective therapies to restore normal immune function in genetically defined patient populations. The enterprise specifically targets elevated soluble interleukin-7 receptor levels, which are directly driven by specific single nucleotide polymorphisms within the immune system. To achieve this targeted intervention, the organization utilizes monoclonal antibodies and antisense oligonucleotides designed to inhibit this receptor without causing broader systemic immunosuppression. This precision medicine approach is currently directed at four primary autoimmune conditions, specifically focusing on rheumatoid arthritis, lupus, lupus nephritis, and type 1 diabetes. Operating within the broader biopharmaceutical sector, the firm advances its specialized clinical pipeline through standard biotechnology research and development frameworks. The exact founding year and the identities of the original founders of Autoimmunity BioSolutions remain publicly undisclosed at this time.
Autoimmunity BioSolutions has raised $2.0M in total across 1 funding round.
Autoimmunity BioSolutions's investors include Eos Bioinnovation.
Autoimmunity BioSolutions has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in November 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 28, 2024 | $2M Seed | EOS Bioinnovation | — | Announced |